Tumor growth curves are shown in Figure 2E, demonstrating superiority of anti–PD-1/lenvatinib to other treatment groups, followed by the combination of anti–PD-1/anti-VEGF, with 1/19 and 6/20 mice requiring sacrifice for tumors larger than or equal to 1,000 mm3. Here, VEGFA is linked to neoplasm.